

Клинические испытания

- 1.** Drago L, De Vecchi E, Valli M, Nicola L, Lombardi A, Gismondo MR. Colonizzazione intestinale di *Lactobacillus casei* subsp.
- 2.** Radicioni M, Koirala R, Fiore W, Leuratti C, Guglielmetti S, Arioli S. Survival of *L. casei* DG® (*Lactobacillus paracasei* CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. *Eur J Nutr.* 2019 Dec;58(8):3161-3170. doi:
- 3.** Arioli S, Koirala R, Taverniti V, Fiore W, Guglielmetti S. Quantitative Recovery of Viable *Lactobacillus paracasei* CNCM I-1572 (*L. casei* DG®) After Gastrointestinal Passage in Healthy Adults. *Front Microbiol.* 2018 Aug 2;9:1720. doi:
- 4.** Ferrario C, Taverniti V, Milani C, Fiore W, Laureati M, De Noni I, Stuknyte M, Chouaia B, Riso P, Guglielmetti S. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with *Lactobacillus paracasei* DG varies among healthy
- 5.** Altaha, B. M., Wadi, J. and Shehabi, A. A. (2018) "Detection Probiotic's DNA of *Lactobacillus paracasei* in Healthy Human
- 6.** D'Incà R, Barollo M, Scarpa M, Grillo AR, Brun P, Vettorato MG, Castagliuolo I, Sturniolo GC. Rectal administration of *Lactobacillus casei* DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild
- 7.** Balzaretti S, Taverniti V, Guglielmetti S, Fiore W, Minuzzo M, Ngo HN, Ngere JB, Sadiq S, Humphreys PN, Laws AP. A Novel Rhamnose-Rich Hetero-exopolysaccharide Isolated from *Lactobacillus paracasei* DG Activates THP-1 Human Monocytic Cells.
- 8.** Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM, Valsecchi C, Tagliacarne C, Fiore W, Bellini M, Bertani L, Gambaccini D, Cicala M, Germanà B, Vecchi M, Pagano I, Barbaro MR, Bellacosa L, Stanghellini V, Barbara G. Effect
- 9.** Compare D, Rocco A, Coccoli P, Angrisani D, Sgamato C, Iovine B, Salvatore U, Nardone G. *Lactobacillus casei* DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel
- 10.** Turco F, Andreozzi P, Palumbo I, Zito FP, Cargioli M, Fiore W, Gennarelli N, De Palma GD, Sarnelli G, Cuomo R. Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of *L. casei* DG®
- 11.** Tursi A, Brandimarte G, Giorgetti GM, Modeo ME. Effect of *Lactobacillus casei* supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure *Helicobacter pylori*
- 12.** Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for *Helicobacter pylori* eradication in Italy. *World J Gastroenterol.* 2015 Jun
- 13.** Rosania R, Giorgio F, Principi M, Amoruso A, Monno R, Di Leo A, Ierardi E. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. *Curr Clin*
- 14.** Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or *Lactobacillus casei* in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. *J Clin*
- 15.** Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or *Lactobacillus casei* in maintaining long-term remission
- 16.** Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G, Rodino S, D'Amico T, Sacca N, Portincasa P, Capezzuto E, Lattanzio R, Spadaccini A, Fiorella S, Polimeni F, Polimeni N, Stoppino V, Stoppino G, Giorgetti GM, Aiello F, Danese S.
- 17.** Bretto E, D'Amico F, Fiore W, Tursi A, Danese S. *Lactobacillus paracasei* CNCM I 1572: A Promising Candidate for
- 18.** Guida F, Turco F, Iannotta M, De Gregorio D, Palumbo I, Sarnelli G, Furiano A, Napolitano F, Boccella S, Luongo L, Mazzitelli M, Usiello A, De Filippis F, Iannotti FA, Piscitelli F, Ercolini D, de Novellis V, Di Marzo V, Cuomo R, Maione S.
- 19.** Cai T, Gallelli L, Cione E, Perletti G, Ciarleglio F, Malossini G, De Pretis G, Palmieri A, Mirone V, Bartoletti R, Johansen TEB. The use of *Lactobacillus casei* DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by
- 20.** Castagliuolo I, Scarpa M, Brun P, Bernabe G, Sagheddu V, Elli M, Fiore W, De Vitis V, Guglielmetti S. Co-administration of vitamin D3 and *Lacticaseibacillus paracasei* DG increase 25-hydroxyvitamin D serum levels in mice. *Ann Microbiol.*
- 21.** Zambori C, Morvay AA, Sala C, Licker M, Gurban C, Tanasie G, Tirziu E. Antimicrobial effect of probiotics on bacterial
- 22.** Хлынов И. Б., Хлынова Р. И., Воронова Е. И., Гаранина Е. В., Гурикова И. А., Кобзарь Т. И., Лосева М. Э., Одинец С. В., Рябинина О. А., Сагутдинова Л. Т., Фрезе Е. Б. ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ *LACTOBACILLUS PARACASEI* CNCM
- 23.** MICROBIOTA AND IMMUNE MICROENVIRONMENT IN POUCHITIS (MEP1): INTERIM ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL
ON ORAL ADMINISTRATION OF *LACTOBACILLUS CASEI* DG FOR 8 WEEKS AFTER ILEOSTOMY CLOSURE Imerio Angriman. Melania Scarpa. Renata D'Inca. Matteo Martinato. Andromachi
- 24.** Taverniti V, Cesari V, Gargari G, Rossi U, Biddau C, Lecchi C, Fiore W, Arioli S, Toschi I, Guglielmetti S. Probiotics Modulate Mouse Gut Microbiota and Influence Intestinal Immune and Serotonergic Gene Expression in a Site-Specific Fashion. *Front*
- 25.** Salaris C, Scarpa M, Elli M, Bertolini A, Guglielmetti S, Pregliasco F, Brun P, Castagliuolo I. *Lacticaseibacillus paracasei* DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells. *Gut Microbes.* 2021 Jan-Dec;13(1):1961970. doi: